5 / 7
Page 18
Notes:
allied
academies
Microbiology: Current Research
Volume 2
International Conference on
Emerging Diseases, Outbreaks & Case Studies
&
16
th
Annual Meeting on
March 28-29, 2018 | Orlando, USA
Influenza
T
he only cost-effective protection against influenza is
vaccination. Due to rapid mutation continuously, new
subtypes appear which require annual immunization. For
a correct vaccination recommendation, the circulating
influenza strains have to be detected promptly and exactly
and characterized regarding their antigenic properties. Due
to recurring incidents of vaccine mismatches, there is a great
need to speed up the process chain from identifying the
right vaccine strains to their administration. The monitoring
of subtypes as part of this process chain is carried out by
national reference laboratories within the WHO Global
Influenza Surveillance and Response System (GISRS). To this
end, thousands of viruses from patient samples (e.g. throat
smears) are isolated and analyzed each year. Currently, this
analysis involves complex and time-intensive (several weeks)
animal experiments to produce specific hyper immune sera
in ferrets, which are necessary for the determination of
the antigen profiles of circulating virus strains. These tests
also bear difficulties in standardization and reproducibility,
which restricts the significance of the results. To replace this
test, a peptide-based assay for influenza virus subtyping is
developed. The differentiation of the viruses takes place by
a set of specifically designed peptidic recognition molecules
which interact differently with the different influenza
virus subtypes. The differentiation of influenza subtypes
is performed by pattern recognition guided by machine
learning algorithms, without any animal experiments.
Speaker Biography
Henry Memczak has studied Nanotechnology at the University of Kassel, Germany and
completed his PhD in Biochemistry in 2014 at the University of Potsdam, Germany and
the Fraunhofer Institute for Cell Therapy and Immunology, Germany. He has worked
on the development of analytical biosensors for influenza detection and methods
for Peptide-Based Bio Interaction Analysis for several years, he did\ publishing in
published several papers, holds two patents and Co-founded the company QPA Bio
Analytics GmbH for the commercialization of novel peptide biochips. For his dedicated
translational research, he received several Awards and Scholarships.
e:
memczak@uni-potsdam.deDiscrimination of subtypes for influenza surveillance using a peptide-based detection platform(flu type)
Henry Memczak, Marc Hovestädt, Bernhard A Y, Sandra Sänger, Jan Grzegorzewski, Matthias König, Thorsten Wolff
and
Frank F Bier
University of Potsdam, Germany